Medical software company Aiosyn has launched a new artificial intelligence (AI) kidney suite for renal disease research.
The new platform, which leverages advanced deep learning technology, enables biopharma and research organisations to analyse kidney structures and quantify lesions that affect kidney health.
Utilising AI-powered computational pathology algorithms, the new suite will objectively quantify kidney lesion scores to improve reproducibility and expedite drug development.
It assists in the identification and characterisation of pathological processes, providing a better avenue for significant enhancements in chronic kidney disease (CKD) research and clinical trials.
The platform helps overcome the limitations of the Banff classification, which is presently used in renal biopsy analysis and suffers from observer variability and depends on qualitative evaluations.
Aiosyn CEO Patrick de Boer said: “The platform will enable researchers to identify new and existing CKD biomarkers to study specific patient subgroups.
“With these new algorithms and AI capabilities, we provide CKD researchers with new tools to complement existing biomarker projects and help to advance CKD precision medicine.”
The availability of the kidney AI suite follows the recent introduction of Aiosyn Mitosis Research.
Furthermore, the company is focused on the development of advanced deep-learning algorithms to identify cancer biomarkers.
In May this year, Aiosyn, Radboud University Medical Centre and Pathologie-DNA secured a €1.3m ($1.4m) EFRO-OOST grant to accelerate AI technology development for breast and skin cancer diagnostics.
Through the AIRAT project, the three organisations will work together to launch CE-marked deep learning algorithms for automated mitosis detection into the market.
